RESUMO
The presentation of illness, response to treatment, and complications of therapy of 15 patients with hepatic metastases of choriocarcinoma are analyzed. The majority of patients received multiagent chemotherapy concomitantly with whole-liver irradiation. Two patients are now in sustained remission. Hepatotoxicity of this combined treatment regimen directly contributed to only one death in the 13 nonsurviving patients. The diagnosis, management, and prognostic significance of choriocarcinoma metastatic to the liver are discussed.
Assuntos
Coriocarcinoma/patologia , Neoplasias Hepáticas/secundário , Neoplasias Uterinas/patologia , Adulto , Coriocarcinoma/mortalidade , Coriocarcinoma/terapia , Terapia Combinada , Feminino , Humanos , Prontuários Médicos , Pessoa de Meia-Idade , Gravidez , Prognóstico , Neoplasias Uterinas/mortalidade , Neoplasias Uterinas/terapiaRESUMO
Eight ovulatory women participated in the preliminary evaluation of a new method of contraception. The technique consisted of subdermal implantation of a biodegradable capsule capable of controlled release of levonorgestrel. The study spanned five menstrual cycles: three observation cycles to confirm ovulation, a cycle with the capsule implanted, and a follow-up observation cycle after its removal. All subjects who were sexually active relied on barrier contraception during the study. Basal body temperature determinations were made throughout all five cycles, and the last three cycles included serum assays of luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone, and levonorgestrel on days 5, 8 to 18, and 22. All subjects except one experienced suppression of ovulation while the capsule was in place. No serious adverse effects were encountered. These results would seem to justify a larger clinical trial to assess the actual efficacy of this contraceptive method.
Assuntos
Anticoncepcionais/administração & dosagem , Estrogênios/sangue , Gonadotropinas/sangue , Norgestrel/farmacologia , Progesterona/sangue , Biodegradação Ambiental , Temperatura Corporal , Cápsulas , Anticoncepcionais Orais Combinados/administração & dosagem , Anticoncepcionais Orais Combinados/farmacologia , Preparações de Ação Retardada , Feminino , Humanos , Levanogestrel , Norgestrel/administração & dosagem , Ovulação/efeitos dos fármacosRESUMO
Thirteen women with infertility thought due to anovulation were treated with LRH. Etiologic diagnoses of amenorrhea included hypothalamic or "idiopathic" and PCOD. All patients had normal gonadotropins and otherwise normal endocrinologic and infertility evaluations; none had ovulated with clomiphene. Patients were studied for six 35 day cycles, single blind, and received LRH or placebo by subcutaneous injections for 28 days/cycle (LRH dosage 1.0 mg 2 or 3 times each day). Frequent assessments of physical status, cervical mucus, vaginal cytology, and serum LH, FSH, estrogen, and progesterone were performed. Ovulation was documented by basal temperature, serum progesterone and, on occasion, endometrial biopsy. Follow-up was continued for 6 months after therapy. Of the 13 patients treated, eight have ovulated and five have conceived. There were no complications of therapy.